Navigation Links
Noble Capital Markets Initiates Research Coverage on ESSA Pharma Inc. (EPIX)
Date:2/17/2017

NEW YORK, Feb. 17, 2017 /PRNewswire/ -- Noble Capital Markets announced today that it has initiated research coverage on ESSA Pharma Inc. (Nasdaq: EPIX). The report was issued by Noble's Head of Biotechnology Research, Kumar Raja, PhD.

ESSA Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments for castration resistant prostate cancer (CRPC). Its lead compound EPI-506, is a small molecule oral drug that selectively blocks the amino-terminal domain of the androgen receptor, thereby has potential to overcome some of the known androgen receptor dependent resistance mechanisms of CRPC. EPI-506 is in Phase 1/2 trial for the treatment of castration-resistant prostate cancer and based on it differentiated mechanism of action could potentially lead to increased progression-free and overall survival compared to the drugs approved for treatment of CRPC.  The full report and disclosures can be accessed by clicking here.

For further information please contact Steve Rashkin at 561-994-5738 or srashkin@noblecapitalmarkets.com

About Noble Capital Markets (www.noblecapitalmarkets.com)

Noble Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton (HQ), New York and Boston. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences such as the Media, Finance & Investor Conference offered in partnership with the National Association of Broadcasters (NAB).

Members: FINRA, SIPC, MSRB

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Please see disclosure, valuation methods, price charts, and ratings histories available in the complete research report, available by clicking here or contacting Noble Capital Markets  at 561-994-5738. The securities covered by or mentioned in the reports involve substantial risk and should generally be purchased only by investors able to accept such risk.

Related Links: www.noblecapitalmarkets.com

Noble Capital Markets is a member of the Financial Industry Regulatory Authority, CRD number 15768.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/noble-capital-markets-initiates-research-coverage-on-essa-pharma-inc-epix-300409340.html


'/>"/>
SOURCE Noble Capital Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at NobleCon13 - Noble Capital Markets Thirteenth Annual Investor Conference
2. Delcath Systems To Present At The NobleCon13 - Noble Capital Markets Thirteenth Annual Investor Conference On January 31, 2017
3. West and Noble Collaborate to Improve Patient Education and Training for Self-Injection Systems
4. ContraVir Pharmaceuticals to Present at NobleCon12
5. BioSpecifics Technologies Corp. to Present at the Noble Financial Capital Markets NobleCon12
6. Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform
7. Echo Therapeutics to Present at the Noble Financial Capital Markets Tenth Annual Equity Conference
8. Aralez to Present at the RBC Capital Markets Global Healthcare Conference
9. Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
10. ML Capital Group to Present 2017 Forecast Tomorrow January 19 2017 Following Record Q4 Sales and Entry Into Cannabis Sector
11. Landauer Agrees to Appoint Jeffrey A. Strong to Board of Directors and Announces Agreement with Gilead Capital LP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... , ... September 11, 2019 , ... ... headquartered in Irving, Texas, that exclusively serves premier oral and maxillofacial surgeons – ... an oral and maxillofacial surgery practice with three locations in the Atlanta area. ...
(Date:9/11/2019)... ... September 11, 2019 , ... Genedata, the leading ... globally operating Finnish pharmaceutical company, has licensed Genedata Biologics® to support their R&D ... , “As part of our strategy to expand our biopharmaceutical R&D operations, ...
(Date:9/11/2019)... ... September 10, 2019 , ... Women’s Excellence is pleased ... recognition of Breast Cancer Awareness Month. In additional to standard weekly appointments, Women's ... 26, 2019 , Women’s Excellence has earned ACR accreditation for mammography services. The ...
Breaking Medicine Technology:
(Date:9/8/2019)... , ... September 06, 2019 , ... ... a historic milestone as its fall 2019 enrollment has reached an all-time high ... students) in master’s and doctoral level candidates, totaling 374 students. The total does ...
(Date:9/8/2019)... ... September 06, 2019 , ... The Plantrician Project is pleased to introduce ... Nutrition Healthcare Conference, where close to 1000 medical professionals from 25 countries, will ... to the use of whole food, plant-based nutrition in clinical practice. ...
(Date:9/8/2019)... ... September 07, 2019 , ... Messaging Architects, an eMazzanti Technologies ... recent successful GroupWise to Office 365 email migration on the Messaging Architects website. ... healthcare organization. , The informative article discusses the tight timeline faced by the ...
(Date:9/4/2019)... ... September 04, 2019 , ... Strategic Radiology has engaged Dan ... practices, representing 28 group practices and more than 1,100 radiologists. , Schriger is ... health care. From 2013 until recently, Dan was director of sales and business ...
(Date:9/4/2019)... ... September 04, 2019 , ... R3 Stem ... 18-19th, 2019. The nation's leading hands-on regenerative training course includes two days of ... is $1000 off, and each attendee also receives a free stem cell procedure ...
Breaking Medicine News(10 mins):